Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial

Abstract Aims Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI) sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been evaluated, its effects on functional capacity in patients with HF and ejection fraction (EF) >40% has yet...

Full description

Bibliographic Details
Main Authors: Rolf Wachter, Sanjiv J. Shah, Martin R. Cowie, Peter Szecsödy, Victor Shi, Ghionul Ibram, Ziqiang Zhao, Jianjian Gong, Sven Klebs, Burkert Pieske
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:ESC Heart Failure
Subjects:
Heart failure with preserved ejection fraction
Heart failure with mid‐range ejection fraction
Functional capacity
Quality of life
Neprilysin inhibition
Randomized controlled trial
Online Access:https://doi.org/10.1002/ehf2.12694

Internet

https://doi.org/10.1002/ehf2.12694

Similar Items